<DOC>
	<DOCNO>NCT01403103</DOCNO>
	<brief_summary>This pilot clinical trial study cholecalciferol treat patient colorectal cancer . The use cholecalciferol may slow disease progression patient colorectal cancer .</brief_summary>
	<brief_title>Cholecalciferol ( 25-OH-Vitamin D ) Treating Patients With Colorectal Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To compare expression 15-hydroxyprostaglandin dehydrogenase ( PGDH ) messenger ribonucleic acid ( mRNA ) protein level tumor tissue baseline treatment 25-hydroxy ( OH ) -vitamin D3 ( cholecalciferol ) . II . To compare expression 15-PGDH mRNA protein level normal colorectal mucosa baseline follow treatment 25-OH-vitamin D3 . SECONDARY OBJECTIVES : I . To compare expression cyclooxygenase ( COX ) -1 COX-2 mRNA tumor tissue baseline treatment 25-OH-vitamin D3 . II . To compare level prostaglandin E2 ( PGE2 ) tumor tissue baseline treatment 25-OH-vitamin D3 . III . To compare expression COX-1 COX-2 mRNA normal colorectal mucosa baseline treatment 25-OH-vitamin D3 . IV . To compare level PGE2 normal colorectal mucosa baseline treatment 25-OH-vitamin D3 . V. To evaluate tolerability single 100,000 international unit ( IU ) dose 25-OH-vitamin D3 . OUTLINE : Patients receive cholecalciferol orally ( PO ) 7 day prior schedule surgery endorectal ultrasound . Patients follow surgery endorectal ultrasound . In case vitamin-D-related toxicity , patient follow resolution toxicity , 6 month .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma , Mucinous</mesh_term>
	<mesh_term>Cystadenocarcinoma</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Patients suspect diagnosis adenocarcinoma rectum sigmoid colon ( e.g . base appearance mass histology ) refer colorectal surgery expect undergo routine proctosigmoidoscopy flexible sigmoidoscopy surgeon 's office well resection and/or endorectal ultrasound ( EUS ) part routine care The tumor must accessible biopsy suitable multiple biopsy Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 2 Able understand willing sign write informed consent document Prior anticancer therapy cancer chemotherapy , biologic therapy , immune therapy radiation therapy Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Unable swallow capsule Underlying condition interfere absorption orally ingest vitamin D , e.g. , untreated fat malabsorption History allergic reaction cholecalciferol vitamin D preparation EXCLUSION CRITERIA FOR DOSING VITAMIN D : Elevated ionized calcium Primary hyperparathyroidism Renal failure estimate glomerular filtration rate &lt; 20 mL/min/1.73m^2 calculate use Modification Diet Renal Disease ( MDRD ) study equation isotope dilution mass spectrometry ( IDMS ) traceable creatinine method report University Hospital Case Medical Center ( UHCMC ) laboratory ( due less active formation 1,25 hydroxyvitamin D due less hydroxylase ) Serum 25OHvitamin D &gt; 40 ng/ml</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>